Text and Data Mining valid from 2018-10-23
Received: 21 January 2018
Accepted: 3 October 2018
First Online: 23 October 2018
Ethics approval and consent to participate
: The study entitled “Feasibility of concomitant cisplatin with hypofractionated radiotherapy for locally advanced head and neck squamous cell carcinoma” was conducted according to the Helsinky declaration. The protocol was approved by the Internal Review Board of the Barrretos Cancer Hospital/Fundação PIO XII and it is registered inthe Brazilian Platform of Ethics in Research (ExternalRef removed) under the registration Number <b>CAAE:</b> 32147014.4.0000.5437. All patients provided specific written informed consent prior to participating in this trial. The study was also registered at ExternalRef removed under the number NCT03194061.
: Not applicable
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.